Venus Remedies gained on Thursday after it has extended its footprint in Latin America with marketing authorization from meropenem from Venezuela, a USD 6 billion pharmaceutical market.

The company is planning to launch meropenem in Venezuela in the next couple of months. The USD 10 million meropenem market in Venezuela offers a great opportunity to us and we are aiming to capture a sizeable market in the first year of the launch, the company said.

Shares of the company gained Rs 16.75, or 6.72%, to trade at Rs 266. The total volume of shares traded was 65,813 at the BSE (3.25 p.m., Thursday).

The scrip has touched an intra-day high of Rs 273.50 and low of Rs 247.75. The total volume of shares traded at the BSE is 65,813.

In the earlier session, the shares gained 2.78%, or Rs 6.75, at Rs 249.25.

Currently, the stock is trading down 25.71% from its 52-week high of Rs 358.05 and above 90% over the 52-week low of Rs 140.